View ValuationXencor 将来の成長Future 基準チェック /26Xencor利益と収益がそれぞれ年間2.1%と28.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に0% 8.5%なると予測されています。主要情報2.1%収益成長率8.54%EPS成長率Biotechs 収益成長21.0%収益成長率28.2%将来の株主資本利益率0%アナリストカバレッジGood最終更新日08 Apr 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesXencor, Inc., Annual General Meeting, Jun 16, 2026Apr 28Xencor Highlights Corporate Priorities and 2026 Pipeline MilestonesJan 08Xencor, Inc. Presents Initial Data for XmAb819, a First-In-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell CarcinomaOct 25Xencor Appoints Raymond Deshaies, Ph.D., to Board of DirectorsAug 01Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell Small Cap Comp Growth IndexJun 30+ 7 more updatesXencor, Inc. Announces Retirement of Nancy Valente as Chief Development OfficerMay 10Xencor Announces Positive Interim Results from First-In-Human Healthy Volunteer Study of Xmab942, A High-Potency Extended Half-Life Anti-Tl1a Antibody, in Development for Treatment of Inflammatory Bowel DiseaseApr 30Xencor, Inc., Annual General Meeting, Jun 12, 2025Apr 24Xencor Appoints Todd Simpson to Board of DirectorsMar 14Now 22% overvalued after recent price rise Nov 12Third quarter 2024 earnings released: US$0.70 loss per share (vs US$0.40 loss in 3Q 2023) Nov 07Xencor, Inc. Doses First Subject in Phase 1/2 Study of XmAb®?942 in Development for Patients with Inflammatory Bowel DiseaseNov 05Now 22% overvalued after recent price rise Oct 11Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as DirectorOct 04Now 24% overvalued after recent price rise Sep 16Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.Sep 12+ 1 more updateNow 28% undervalued after recent price drop Aug 09New minor risk - Shareholder dilution Aug 07Second quarter 2024 earnings released: US$1.07 loss per share (vs US$0.37 loss in 2Q 2023) Aug 06First quarter 2024 earnings released: US$1.11 loss per share (vs US$1.02 loss in 1Q 2023) May 10New minor risk - Shareholder dilution Apr 26Xencor Appoints Bart Cornelissen as Senior Vice PresidentApr 10Co-Founder recently sold €270k worth of stock Mar 10New minor risk - Profitability Feb 29Full year 2023 earnings released: US$2.08 loss per share (vs US$0.93 loss in FY 2022) Feb 28Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024Feb 21Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate StrategyJan 02Third quarter 2023 earnings released: US$0.40 loss per share (vs US$0.55 loss in 3Q 2022) Nov 08Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023Nov 01John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024Oct 28Xencor Announces Planned Retirement of Senior Vice President John KuchOct 27Xencor, Inc. Appoints Barbara J. Klencke to Board of DirectorsSep 20Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.57 loss in 2Q 2022) Aug 06Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023Jul 29Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 CongressMay 31Insufficient new directors May 10First quarter 2023 earnings released: US$1.02 loss per share (vs US$0.40 profit in 1Q 2022) May 09Co-Founder recently sold €172k worth of stock Mar 09Full year 2022 earnings released: US$0.93 loss per share (vs US$1.42 profit in FY 2021) Feb 25Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023Feb 17Senior VP & Chief Medical Officer recently sold €95k worth of stock Dec 26Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual MeetingDec 13Third quarter 2022 earnings released: US$0.55 loss per share (vs US$0.69 loss in 3Q 2021) Nov 09Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical StudyNov 08Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022Nov 01High number of new directors Oct 31Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual MeetingOct 06High number of new directors Sep 13Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of DirectorsSep 10Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.90 profit in 2Q 2021) Aug 04Xencor, Inc. to Report Q2, 2022 Results on Aug 03, 2022Jul 28Investor sentiment improved over the past week Jul 09Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive IndexJun 26Investor sentiment improved over the past week Jun 24Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid TumorsMay 27First quarter 2022 earnings released: EPS: US$0.40 (vs US$0.043 loss in 1Q 2021) May 07Co-Founder recently sold €65k worth of stock Mar 11Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 25Xencor, Inc. to Report Q4, 2021 Results on Feb 23, 2022Feb 17Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual MeetingDec 13Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).Nov 23Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.22 loss in 3Q 2020) Nov 10Director Yujiro Hata has joined 3rd company board Aug 24Second quarter 2021 earnings released: EPS US$0.90 (vs US$0.61 loss in 2Q 2020) Aug 06Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 3000E Value IndexJun 28+ 5 more updatesSotrovimab Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19May 27First quarter 2021 earnings released: US$0.043 loss per share (vs US$0.14 loss in 1Q 2020) May 07Xencor, Inc. Doses First Subject in Phase 1 Study of XMAB®564, an Engineered IL-2 Cytokine in Development for Autoimmune DiseasesApr 29Co-Founder recently sold €106k worth of stock Mar 06Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® TherapeuticsFeb 26Full year 2020 earnings released: US$1.21 loss per share (vs US$0.47 profit in FY 2019) Feb 25Revenue beats expectations Feb 25Xencor, Inc. to Report Q4, 2020 Results on Feb 23, 2021Feb 17New 90-day high: €42.20 Feb 08Xencor, Inc. and The University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with CancerJan 08New 90-day high: €38.20 Jan 07Senior VP & Chief Medical Officer recently sold €135k worth of stock Dec 19Miragen Therapeutics, Inc. Enters Technology License Agreement with Xencor, IncDec 19New 90-day high: €37.20 Dec 15Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual MeetingNov 10Revenue misses expectations Nov 07Third quarter 2020 earnings released: US$0.22 loss per share Nov 07Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia At the 2020 Ash Annual MeetingNov 06Xencor, Inc. to Report Q3, 2020 Results on Nov 05, 2020Oct 30Xencor, Inc. to Present Data from the Phase 1 Study of XmAb 20717 and Three Research Programs at the SITC Annual MeetingOct 15業績と収益の成長予測DB:XE9 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028162-250-178-167912/31/2027138-250-219-1971312/31/2026117-237-211-2121312/31/2025126-92-138-135N/A9/30/2025150-131-138-133N/A6/30/2025147-171-137-131N/A3/31/2025127-208-171-162N/A12/31/2024110-233-212-202N/A9/30/2024109-213-143-134N/A6/30/2024150-191-143-133N/A3/31/2024172-146-115-104N/A12/31/2023175-133-99-78N/A9/30/2023145-119-151-121N/A6/30/2023113-128-136-94N/A3/31/202398-140-64-12N/A12/31/2022165-55-1924N/A9/30/20222973072111N/A6/30/2022289224573N/A3/31/2022327109219N/A12/31/202127583-33-17N/A9/30/2021163-4-75-62N/A6/30/202117924-42-26N/A3/31/2021124-64-58-44N/A12/31/2020123-69-19-5N/A9/30/202084-83-55-42N/A6/30/202071-80-55-44N/A3/31/202077-618093N/A12/31/2019157275364N/A9/30/201916536N/A67N/A6/30/201917249N/A63N/A3/31/201915339N/A-74N/A12/31/201841-70N/A-80N/A9/30/201859-45N/A-70N/A6/30/201830-71N/A-63N/A3/31/201843-53N/A-47N/A12/31/201746-38N/A-34N/A9/30/201722-55N/A-43N/A6/30/201730-40N/A95N/A3/31/20178415N/A98N/A12/31/201610945N/A95N/A9/30/201610340N/A107N/A6/30/20169938N/A12N/A3/31/201634-18N/A14N/A12/31/201528-18N/A27N/A9/30/201512-27N/A25N/A6/30/20159-23N/A-20N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: XE9今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: XE9今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: XE9今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: XE9の収益 ( 28.2% ) German市場 ( 6.2% ) よりも速いペースで成長すると予測されています。高い収益成長: XE9の収益 ( 28.2% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: XE9 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/04 15:53終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Xencor, Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関Peter LawsonBarclaysEtzer DaroutBarclaysZhiqiang ShuBerenberg21 その他のアナリストを表示
Xencor, Inc. Presents Initial Data for XmAb819, a First-In-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell CarcinomaOct 25
Xencor Announces Positive Interim Results from First-In-Human Healthy Volunteer Study of Xmab942, A High-Potency Extended Half-Life Anti-Tl1a Antibody, in Development for Treatment of Inflammatory Bowel DiseaseApr 30
Xencor, Inc. Doses First Subject in Phase 1/2 Study of XmAb®?942 in Development for Patients with Inflammatory Bowel DiseaseNov 05
Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.Sep 12+ 1 more update
Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 CongressMay 31
Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual MeetingDec 13
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical StudyNov 08
Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual MeetingOct 06
Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid TumorsMay 27
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual MeetingDec 13
Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).Nov 23
Xencor, Inc. Doses First Subject in Phase 1 Study of XMAB®564, an Engineered IL-2 Cytokine in Development for Autoimmune DiseasesApr 29
Xencor, Inc. and The University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with CancerJan 08
Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual MeetingNov 10
Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia At the 2020 Ash Annual MeetingNov 06
Xencor, Inc. to Present Data from the Phase 1 Study of XmAb 20717 and Three Research Programs at the SITC Annual MeetingOct 15